Johnson & Johnson stock page - price, fundamentals, dividends - iOCharts

Ticker
JNJ

Price
173.94
Stock movement down
-1.56 (-0.89%)
Company name
Johnson & Johnson
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
457.71B
Ent value
550.89B
Price/Sales
4.82
Price/Book
-
Div yield
2.60%
Div growth
5.87%
Growth years
58
FCF payout
51.18%
Trailing P/E
23.08
Forward P/E
15.93
PEG
3.61
EPS growth
-0.30%
1 year return
1.68%
3 year return
7.99%
5 year return
6.50%
10 year return
10.58%
Last updated: 2022-05-19

BUSINESS INSIGHT

Segment Revenues ($M)

Loading...
Operations comments

In 21Q1 JNJ COVID-19 Vaccine authorized by U.S. FDA for emergency use

In 21Q1 JNJ Single-Shot COVID-19 Vaccine granted emergency use listing by the World Health Organization

In 21Q1 JNJ Single-Shot COVID-19 Vaccine granted conditional marketing authorization by European Commission

The company has not provided an official guidance for COVID-19 Vaccine revenues and margins for 2021

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share4.52
Dividend yield2.60%
Payout frequencyQuarterly
Maximum yield3.64%
Average yield2.66%
Minimum yield2.27%
Discount to avg yield-2.40%
Upside potential-2.35%
Yield as % of max yield71.49%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield2.60%
Current yield distribution58.10%
Yield at 100% (Min)2.27%
Yield at 90%2.46%
Yield at 80%2.52%
Yield at 50% (Median)2.65%
Yield at 20%2.81%
Yield at 10%2.90%
Yield at 0% (Max)3.64%

Dividend per share

Loading...
Dividend per share data
Years of growth58 years
CCC statusDividend Champion
Dividend per share4.52
Payout frequencyQuarterly
Ex-div date23 May 2022
EPS (TTM)-
EPS (1y forward)10.92
EPS growth (5y)-0.30%
EPS growth (5y forward)6.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
JNJS&P500
DGR MR6.60%-16.52%
DGR TTM5.38%4.37%
DGR 3 years5.78%3.88%
DGR 5 years5.87%4.73%
DGR 10 years6.42%8.30%
DGR 15 years7.31%5.82%
Time since last change announced31 days
EPS growth (5y)-0.30%
EPS growth (5y forward)6.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM42.22%51.18%
Average--
Forward41.39%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E23.08
Price to OCF23.67
Price to FCF27.98
Price to EBITDA21.83
EV to EBITDA26.28

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.82
Price to Book-
EV to Sales5.81

FINANCIALS

Per share

Loading...
Per share data
Current share count2.63B
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)94.88B
Gross profit (TTM)64.49B
Operating income (TTM)24.33B
Net income (TTM)19.83B
EPS (TTM)-
EPS (1y forward)10.92

Margins

Loading...
Margins data
Gross margin (TTM)67.97%
Operating margin (TTM)25.64%
Profit margin (TTM)20.90%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash10.46B
Net receivables15.59B
Total current assets60.42B
Goodwill34.94B
Intangible assets44.42B
Property, plant and equipment47.70B
Total assets178.35B
Accounts payable9.31B
Short/Current long term debt33.15B
Total current liabilities43.39B
Total liabilities103.65B
Shareholder's equity0.00
Net tangible assets-4.65B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)19.34B
Capital expenditures (TTM)2.98B
Free cash flow (TTM)16.36B
Dividends paid (TTM)8.37B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open174.72
Daily high174.80
Daily low172.69
Daily Volume6.52M
All-time high186.01
1y analyst estimate190.67
Beta0.72
EPS (TTM)-
Dividend per share4.52
Ex-div date23 May 2022
Next earnings date19 Jul 2022

Downside potential

Loading...
Downside potential data
JNJS&P500
Current price drop from All-time high-6.49%-18.47%
Highest price drop-38.78%-56.47%
Date of highest drop11 Aug 19939 Mar 2009
Avg drop from high-9.42%-11.34%
Avg time to new high19 days12 days
Max time to new high1038 days1805 days
COMPANY DETAILS
JNJ (Johnson & Johnson) company logo
Marketcap
457.71B
Marketcap category
Large-cap
Description
Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and healthcare professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Employees
144000
SEC filings
CEO
Alex Gorsky
Country
USA
City
New Brunswick
Stock type
Common stock
CCC status
Dividend Champion
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
We discuss areas that could outperform in the current market environment.
May 19, 2022
Companies could be returning trillions to shareholders. Here’s how to accept it.
May 19, 2022
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
May 19, 2022
India has supplied COVID-19 vaccines to Cambodia and Thailand under an initiative of the Quad group of countries, New Delhi said on Thursday, though not the Johnson & Johnson shot as originally planne...
May 19, 2022
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
May 19, 2022
In this article, we will discuss the 12 best DOW stocks to buy according to hedge funds. If you want to explore similar stock options, you can also take a look at 5 Best DOW Stocks To Buy According To...
May 19, 2022
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
May 18, 2022
In this article, we discuss the 10 best Vanguard dividend stocks with high yields. If you want to skip our detailed analysis of dividend stocks and the latest market situation, go directly to 5 Best V...
May 18, 2022
The new funding will allow Locus Biosciences to advance its clinical development and pursue mergers and acquisitions.
May 18, 2022
Is Johnson & Johnson stock a buy after the company suspended its Covid vaccines guidance? Is JNJ stock a buy right now?
May 17, 2022
Next page